Results 91 to 100 of about 2,831 (235)
Evaluating the efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: a systematic review and meta-analysis. [PDF]
Front Endocrinol (Lausanne)ObjectiveTo compare the clinical efficacy of subthreshold micropulse laser (SML) combined with anti-VEGF drugs versus anti-VEGF drugs monotherapy for diabetic macular edema (DME) through a meta-analysis.MethodsWe systematically reviewed relevant ...
Jiang Y, He W, Qi S.
europepmc +3 more sources
BMC Ophthalmology, 2021 Background This article is a case report of pseudoxanthoma elasticum (PXE) which was diagnosed based on significant angioid streaks (AS) with choroidal neovascularization (CNV) and regain normal visual function by intravitreal injection with Conbercept ...
Chaoxiong Cui +3 more
doaj +1 more source
Driving Innovation: The Impact of National Health Policies on Optometry Research in East Asia
The International Journal of Health Planning and Management, Volume 41, Issue 1, Page 37-46, January 2026.ABSTRACT This study examines the optometric research landscape in three East Asian countries—China, Japan, and Korea—analysing how research trends align with each country's national health strategies. By evaluating published articles and reviews from national journals between 2006 March 2025, we identify key areas of focus, including paediatric ...
Jihye Ahn, Moonsung Choi
wiley +1 more source
Actualización en el tratamiento farmacológico de la degeneración macular asociada a la edad húmeda [PDF]
, 2019 Introducción : La degeneración macular asociada a la edad (DMAE) es una enfermedad degenerativa, siendo la primera causa de ceguera legal en países desarrollados.
Moreno Díaz, Carmen
core
BMC Ophthalmology, 2018 Background Macular neovascular diseases can cause severe vision loss. A newly approved anti—VEGF drug Conbercept has shown good efficacy and safety in rigorous random controlled trials (RCT), however, it cannot fully reflect the clinical application of ...
Jin Jing +7 more
doaj +1 more source
Concentrations of VEGF and PlGF Decrease in Eyes After Intravitreal Conbercept Injection [PDF]
Diabetes Therapy, 2018 Conbercept is a new anti-vascular endothelial growth factor drug approved for the treatment of age-related macular degeneration by the China Food and Drug Administration (CFDA) in 2013. In this study, we for the first time evaluated the concentrations of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) after patients with ...
Jun Zhou +6 more
openalex +3 more sources
[Conbercept reverses TGF-β2-induced epithelial-mesenchymal transition in human lens epithelial cells by regulating the TGF-β/Smad signaling pathway]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoZhu M, Wang J.
europepmc +2 more sources
Acta Ophthalmologica, Volume 103, Issue 7, Page 741-763, November 2025.Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler +17 more
wiley +1 more source
Frontiers in Pharmacology, 2022 Background: The study concerning the influence of Conbercept, which is an anti-Vascular endothelial growth factor (VEGF) agent, in intraocular pressure (IOP) spike is limited and warrants further investigation.
Yunyan Hu +8 more
doaj +1 more source
Journal of International Medical Research, 2020 Objective This study assessed the efficacy of conbercept for patients with non-proliferative diabetic retinopathy (NPDR). Methods In this retrospective clinical study, 54 patients with NPDR (54 eyes) were treated with intravitreal injection of conbercept
Jing Wang +8 more
doaj +1 more source